These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cetuximab. Graham J; Muhsin M; Kirkpatrick P Nat Rev Drug Discov; 2004 Jul; 3(7):549-50. PubMed ID: 15272498 [No Abstract] [Full Text] [Related]
8. Cetuximab in the treatment of metastatic colorectal cancer. Moosmann N; Heinemann V Expert Opin Biol Ther; 2007 Feb; 7(2):243-56. PubMed ID: 17250462 [TBL] [Abstract][Full Text] [Related]
9. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Martinelli E; De Palma R; Orditura M; De Vita F; Ciardiello F Clin Exp Immunol; 2009 Oct; 158(1):1-9. PubMed ID: 19737224 [TBL] [Abstract][Full Text] [Related]
10. Biotech firm faces challenges from FDA, falling stock prices. Reynolds T J Natl Cancer Inst; 2002 Mar; 94(5):326-8. PubMed ID: 11880468 [No Abstract] [Full Text] [Related]
11. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398 [No Abstract] [Full Text] [Related]
12. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Jean GW; Shah SR Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402 [TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. Starling N; Cunningham D Curr Opin Oncol; 2004 Jul; 16(4):385-90. PubMed ID: 15187895 [TBL] [Abstract][Full Text] [Related]
14. Predicting response of molecular targeted therapies: a still possible challenge? Labianca R; Garassino M; Torri V Ann Oncol; 2008 May; 19(5):829-30. PubMed ID: 18296420 [No Abstract] [Full Text] [Related]
16. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer. Caponigro F Anticancer Drugs; 2004 Apr; 15(4):311-20. PubMed ID: 15057134 [TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation. Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341 [TBL] [Abstract][Full Text] [Related]